Powered by

Ovid Therapeutics Announces OV935/TAK-935 Presentations at the American Epilepsy Society 72nd Annual Meeting

Nov 20, 2018 - GlobeNewswire

NEW YORK, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it will present two poster presentations and one oral presentation on OV935/TAK-935 at the American Epilepsy Society (AES) 72nd Annual Meeting, taking place from November 30 December 4, 2018, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

"The oral presentation will report new preclinical work in a genetic seizure model the Dravet syndrome mouse model showing OV935's potential impact on seizure incidence, frequency and severity and improvement in overall survival," said Matthew During, M.D., D.Sc., founder and chief scientific officer of Ovid Therapeutics. "The Dravet mouse model data build upon our previously presented findings on survival benefit on the APP/PS1 transgenic mouse model. Collectively, our preclinical work continues to show the potential of OV935's mechanism of action to make the brain more resistant to hyperexcitation and seiz...